Stroke Drug, NTx-265 Fails P2 Trial, Stem Cell Therapeutics Corp (TSX:SSS.V)
SSS.V reports no statistical differences between the groups and but, the top-line primary endpoint results for the modified REGENESIS P2b stroke trial of NTx (R)-265 in acute stroke showed that there was substantial improvement in the primary endpoint absolute change in NIHSS in both placebo treated patients and those receiving NTx(R)-265. SSS.V expects to report further on the outcome of this within the next 2-3 weeks, together with results from a number of secondary which may provide an alternative to NIHSS as a pathway forwards.
However, the results show that NTx(R)-265 was well tolerated in treated patients with no adverse affect on mortality. Of the 96 patients enrolled in the trial, 72 patients were administered a course of NTx(R)-265, sequential administration of human chorionic gandotropin (hCG) followed by erythropoietin (EPO), with the first dose at 24-48 hours after stroke onset while 24 patients were treated with placebo.
Stem Cell Therapeutics Corp is a public Canadian biotechnology company focused on the development and commercialization of drug-based therapies to treat central nervous system diseases.
